Senti Biosciences Holdings Shareholders Approve Merger at Annual Meeting
Senti Biosciences Holdings stockholders approved the merger agreement with ST NewCo at the reconvened annual meeting on October 15, 2026. Shareholders authorized common stock issuance upon exchange of Senti Holdings’ Senior Secured Convertible Notes. A reverse stock split ranging from 1-for-20 to 1-for-50 received approval, subject to board discretion, including authority to abandon it. Stockholders elected Timothy Lu, Edward Mathers and Frances D. Schulz; ratified KPMG as independent auditor for fiscal 2026. The adjournment proposal was not presented because the merger agreement had secured the required votes. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Senti Biosciences Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-065992), on October 15,
Senti Biosciences Holdings stockholders approved the merger agreement with ST NewCo at the reconvened annual meeting on October 15, 2026. Shareholders authorized common stock issuance upon exchange of Senti Holdings’ Senior Secured Convertible Notes. A reverse stock split ranging from 1-for-20 to 1-for-50 received approval, subject to board discretion, including authority to abandon it. Stockholders elected Timothy Lu, Edward Mathers and Frances D.
Schulz; ratified KPMG as independent auditor for fiscal 2026. The adjournment proposal was not presented because the merger agreement had secured the required votes. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice.
Senti Biosciences Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-065992), on October 15, 2026, and is solely responsible for the information contained therein.
(C)